Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: Implications for patients

Angelo Antonini, Daniela Calandrella

Research output: Contribution to journalArticlepeer-review

Abstract

Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson's disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation. This review summarized the pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed the role of pramipexole in the management of early and advanced PD. The introduction of a once-daily formulation of pramipexole poses significant potential advantages for patients and this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalNeuropsychiatric Disease and Treatment
Volume7
Issue number1
DOIs
Publication statusPublished - 2011

Keywords

  • Advanced Parkinson's disease
  • Continuous drug delivery
  • Early parkinson's disease
  • Extended release
  • Immediate release
  • Pramipexole

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: Implications for patients'. Together they form a unique fingerprint.

Cite this